Babelio Showcases Innovative Baby Safety and Sleep Solutions at ABC Kids Expo 2025
Las Vegas, Nevada--(Newsfile Corp. - May 22, 2025) - Babelio, a trusted name in toddler products, is presenting its core product lines at ABC Kids Expo 2025, held May 21-23 in Las Vegas. By sharing its thoughtfully developed products with leading retailers and industry professionals, Babelio aims to reinforce its presence in the baby and parenting sector and expand global visibility through designs grounded in real-life needs.
Picture 1
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11580/253051_e161fb0df4b9b838_001full.jpg
Founded in 2020 by a team with over a decade of experience in the U.S. baby product industry, Babelio quickly gained traction with families online, especially through Amazon. Today, its product portfolio spans multiple global marketplaces and diverse digital channels-including its official website and an expanding network of digital retail partners. With a primary presence in the U.S. market, Babelio has earned a growing reputation for products that are dependable, functional, and intuitively designed for daily parenting needs.
At this exhibition, Babelio's Safety product line features prominently at the booth with a focus on baby gates built for everyday homes, including:
Pressure Mounted Baby Gate (PressGuard Series)
Hardware Mounted, Trip-Free Baby Gate (Boundless Series)
Cat Door Baby Gate (CatPrivilege Series)
All three gate systems share core features such as auto-close, stay-open functionality, two-way swing, and a dual locking mechanism operable with one hand-offering a consistent balance of security and convenience across different home settings. These gate systems reflect Babelio's focus on creating safe, flexible home spaces without limiting a child's sense of exploration.
Picture 2
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11580/253051_e161fb0df4b9b838_002full.jpg
During the exhibition, Babelio will launch several news products. Studies have shown that sleeping can be one of the most challenging aspects of early parenting, and Babelio addresses this with its compact, travel-friendly white noise solution. Pocket Mini White Noise Sound Machine: This ultra-compact device delivers deep, immersive audio quality rarely found in similarly sized white noise machines. Whether used to aid sleep or soothe fussiness, the Pocket Mini helps create a peaceful environment wherever families go.
Other products include the Gallery Series Suction Baby Plate, tools for Outdoor Play and Feeding, Off-Roader Balance Bike, space-saving playpens, booster seats, carriers, slings, and swaddles-all prioritizing practicality, comfort, and clutter-free functionality.
This appearance at ABC Kids Expo 2025 is a powerful declaration by the Babelio in the baby and parenting sector.In the future, Babelio will continuously explore and innovate, and bring more healthy, safe, and effective baby products to global consumers, working together to create a new future for baby health.
Picture 3
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11580/253051_e161fb0df4b9b838_003full.jpg
About Babeilio
Babelio is built on the spirit of dependable fatherhood-steadfast, protective, and quietly empowering. The brand embraces the idea that great parenting means offering safe boundaries without limiting discovery. Through four product lines-Safety, Sleep, Outdoor, and Feeding-Babelio provides practical tools that support steps, sleep, and exploration, helping families navigate early childhood with clarity and confidence.
For more information, visit www.babeliobaby.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
38 minutes ago
- CTV News
Smith says she sees a ‘breakthrough' in talks with Americans on energy
Alberta Premier Danielle Smith poses for a photo at the Canadian Embassy in Washington, D.C., on Wednesday, June 4, 2025. THE CANADIAN PRESS/Kelly Geraldine Malone WASHINGTON — Alberta Premier Danielle Smith said on Wednesday there's been a 'breakthrough' in conversations with Americans on Canada's role in the United States' quest for energy dominance as President Donald Trump's tariffs continue to cause uncertainty for the bilateral relationship. 'We've managed to make a breakthrough on the discussion about energy dominance and how Canada can lend itself to that, whether its our oil, our gas, critical minerals, uranium from Saskatchewan, electricity from many of our provinces,' Smith said in an interview with The Canadian Press at the embassy in Washington, D.C. 'I feel like there's a real understanding of that.' Trump returned to the White House set on boosting America's energy production. Smith said that while the energy argument has seen success, conversations around other industries are ongoing. The Alberta premier was in the United States capital for meetings and a forum on energy this week as Trump doubled his tariffs on steel and aluminum imports. Canada is a major supplier to the U.S. and Canadian industry says 50 per cent levies will be devastating. Smith said she had conversations with American counterparts and explained that, particularly for aluminum tariffs, they are 'the very definition of a tariff being its own punishment.' The United States imports about 60 per cent of its aluminum from Canada. The Canadian industry largely uses hydroelectricity to make the high energy costs connected to smelting more affordable. Smith said the U.S. doesn't have the ability to develop a homegrown industry to fill the gaps. 'We just have to make sure we are able to make that same (energy) argument on everything else, on the integrated food market, the integrated manufacturing market,' Smith said, also pointing to timber. '(We) haven't had a full breakthrough on all of that but I think the conversations I have are always very positive.' Despite conversations at home about Western alienation and Alberta separatism, Smith said that issue has not come up in Washington. The premier, however, said it's important to take the issue seriously. Trump set his sights on Canada early in his return to the White House and his tariffs on steel, aluminum and automobiles have upended Canadian industries. The president has repeatedly said he doesn't need anything from Canada but his actions have shown signs that he still values trade with America's northern neighbour. Trump slapped Canada with economywide duties in March, only to walk back the tariffs on imports complaint with the Canada-U.S.-Mexico Agreement on trade, called CUSMA, a few days later. Commerce Secretary Howard Lutnick was asked during a U.S. Senate hearing Wednesday about tariffs on Canada. Lutnick pointed to the trilateral agreement and said imports that are compliant with CUSMA remain tariff-free. CUSMA was negotiated during the first Trump administration and was up for a mandatory review next year. Smith said it remains unclear when CUSMA negotiations might start but there is 'encouragement or expectation that we might get some kind of detente or interim agreement by the time we have the G7.' It's unclear whether that will be commitments on CUSMA or a separate agreement on the current tariffs. Carney has said Canada will negotiate a new economic and security agreement with the United States. Canada-U.S. Trade Minister Dominic LeBlanc, who met with Lutnick in Washington Tuesday, said he's 'hopeful that we can get to the best outcome for Canadians.' Carney and Trump will join leaders from France, Germany, Japan, the United Kingdom, Italy and the European Union from June 15 to 17 for the G7 leaders summit in Kananaskis. Mexican President Claudia Sheinbaum has also been invited to attend. Smith said it 'just makes so much sense for Canada and the U.S. to get to an agreement fast.' She said Americans have 'bigger fish to fry' on other major policy priorities. Smith was optimistic about Carney's relationship with Trump. While the president recently brought back comments on making Canada a U.S. state, Trump has also spoken about a good relationship with Carney and calls him prime minister and not the 'governor' title he used to taunt former prime minister Justin Trudeau. It also marks a change in tone for the Alberta premier, who had an icy relationship with Ottawa under Trudeau. Smith has long been critical of the governing Liberal's policies around energy which she says micromanaged Alberta's priorities and hindered industry. She said federal policies stopped Alberta from developing foreign markets that would be critical for many Canadian industries as Trump tries to realign global trade through tariffs. Following the First Ministers' meeting in Saskatoon earlier this week, Smith said she is 'hoping that we are having a breakthrough with the Liberals way of seeing things.' Smith had proposed a bitumen pipeline to B.C.'s northern coast coupled with support for a project on decarbonization. She said 'if we can work together on developing new markets then I think it will be good for everyone.' B.C. deputy premier Niki Sharma has pushed back on Smith's proposal, saying the province is focusing on 'shovel-ready projects, not theoretical projects with no proponents.' This report by The Canadian Press was first published June 4, 2025. Kelly Geraldine Malone, The Canadian Press
Globe and Mail
an hour ago
- Globe and Mail
‘Too Soon to Celebrate,' Says Investor About Tesla Stock
Tesla (NASDAQ:TSLA) bulls have had the June 12th Robotaxi date circled on their calendar for months by now, and the excitement is growing as the day approaches. Confident Investing Starts Here: Though the company has been teasing the idea of self-driving cars for over a decade, its track record has not totally matched the hyperbole of CEO Elon Musk. Indeed, Musk stated way back in 2013 that Tesla was aiming to have the technology to drive 90% of all miles by 2016. Flash forward to the present day, and what was once revolutionary has now become a battlefield full of fierce competition, and Tesla has now clearly fallen behind Google's Waymo for primacy in the self-driving market. Waymo is now operating some 250,000 weekly trips, and has staked out 27% of the local rideshare market in San Francisco. Can the Robotaxi event succeed in flipping the narrative back to Tesla? One investor, known by the pseudonym, Stone Fox Capital advises investors not to pop the champagne bottles just yet. 'Tesla already appears valued based on initial robotaxi success, and this doesn't appear guaranteed,' states the 5-star investor. Stone Fox notes that TSLA is so far behind Waymo that the term 'taking a Waymo' might soon become part of everyday language. Launching a small 10-car pilot program in Austin, the investor argues, isn't exactly the game-changer some investors are hoping for. 'The big risk is that a robotaxi delay continues to allow Waymo to control the market while the robotaxi service launch appears already priced into the stock,' adds Stone Fox. Moreover, some of Musk's recent comments – such as the fact that the 'same strengths and weaknesses' of human drivers will be present with Tesla's FSD technology – are not exactly inspiring confidence. While Stone Fox isn't discounting Tesla's potential to eventually rake in the dollars, the investor doesn't see that happening anytime soon. 'Investors can likely buy Tesla at a lower price once the far-flung excitement disappears, even if the company is on the path to a successful robotaxi business,' concludes Stone Fox Capital, but for now the investor's advice is to steer clear of this one and Sell. (To watch Stone Fox Capital's track record, click here) Meanwhile, Wall Street is firmly divided on this one. With 16 Buy, 10 Hold, and 11 Sell recommendations, TSLA has a consensus Hold (i.e. Neutral) rating. The average price target of $282.70 suggests about 18% downside from current levels – an outlook Stone Fox would likely endorse. (See TSLA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured investor. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Globe and Mail
an hour ago
- Globe and Mail
Multiple Sclerosis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Multiple sclerosis Pipeline Insight 2025' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Multiple Sclerosis Treatment Landscape. Click here to read more @ Multiple Sclerosis Pipeline Outlook Key Takeaways from the Multiple Sclerosis Pipeline Report In May 2025, Novartis Pharmaceuticals announced a Phase IV study in which breastfeeding mothers treated with ofatumumab and their babies are taking part for up to 1 year. The study consists of a Core Part and a Safety Follow-up Part. The Core Part includes a Screening period and a Sampling period. During the Screening period (up to 4 weeks), the study doctor will assess if mothers can join the study. The Sampling period, during which milk samples and a blood sample will be collected, will last for up to 12 weeks. The Safety Follow-up Part will last for about 9 months, to follow up on health and safety of mothers and their babies. In May 2025, Hoffmann-La Roche announced a study will evaluate the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab. In May 2025, Eli Lilly and Company conducted a study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up. In May 2025, Biocad announced a clinical study is to assess the long-term efficacy and safety of BCD-132 (divozilimab) in patients with multiple sclerosis who previously participaded in BCD-132-2 and BCD-132-4/MIRANTIBUS studies. In May 2025, Sanofi conducted a study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. In May 2025, Biogen organized a study is to assess the efficacy of DMF in Chinese participants with RMS at Week 48. The secondary objectives of the study are to assess the efficacy and safety of DMF in Chinese participants with RMS. DelveInsight's Multiple Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple Sclerosis treatment. The leading Multiple Sclerosis Companies such as Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Promising Multiple Sclerosis Therapies such as 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others. Stay informed about the cutting-edge advancements in Multiple Sclerosis treatments. Download for updates and be a part of the revolution in cancer care @ Multiple Sclerosis Clinical Trials Assessment Multiple sclerosis Emerging Drugs Profile IMU-838: Immunic Therapeutics Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. Bolstered by excellent clinical data from the phase II EMPhASIS trial, Immunic believed that vidofludimus calcium has the potential to demonstrate medically important advantages compared with other treatments, particularly for the early treatment of RMS patients, due to its placebo like safety profile and its robust anti-inflammatory and neuroprotective properties. BIIB091: Biogen BIIB091 selectively inhibits Burton's tyrosine kinase (BTK), a non-receptor tyrosine kinase that regulates the development and signaling of B cells and myeloid cells hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of another cell of the immune system, the myeloid cells via another receptor of this cell (Fcγ receptor signaling (FcγRs)). Preclinical studies demonstrated BIB091 to be a high potency molecule with good drug-like properties and a safety/tolerability profile suitable for clinical development as a highly selective, reversible BTKi for treating autoimmune diseases such as MS. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple sclerosis. IMCY-0141: ImCyse IMCY-0141 is the Company's second clinical-stage compound. This Imotope is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of multiple sclerosis. NeuroVax: Immune Response BioPharma NeuroVax contains a combination of three protein fragments (peptides) which appear on the surface of T-cells involved in the immune response in MS. Studies suggested that treatment with NeuroVax stimulates production of certain regulatory T-cells, which in turn decrease the levels of other T-cells which attack myelin. NeuroVax is a Once a Month Dosing injection, safe, tolerable, enhances FOXP3+ Tregs & Regulates Pathogenic T Cells in MS Patients, a first in class disease modifying Multiple Sclerosis Vaccine. NeuroVax IR has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all treated patients. NeuroVax appears to work in part by enhancing levels of Foxp3+ Tregs, which may help regulate expression of pathogenic T cells in MS patients. The three TCR peptides combined in it correspond to one or more TCR gene families which are over expressed in 90% of MS patients. The Multiple Sclerosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Sclerosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis Treatment. Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different Multiple Sclerosis mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Sclerosis market Learn more about Multiple Sclerosis Drugs opportunities in our groundbreaking Multiple Sclerosis research and development projects @ Multiple Sclerosis Unmet Needs Multiple Sclerosis Companies Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Multiple Sclerosis Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Multiple Sclerosis treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives Scope of the Multiple Sclerosis Pipeline Report Coverage- Global Multiple Sclerosis Companies- Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Multiple Sclerosis Therapies- 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others. Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Multiple Sclerosis Pipeline on our website @ Multiple Sclerosis Emerging Drugs and Companies Table of Content Introduction Executive Summary Multiple sclerosis: Overview Pipeline Therapeutics Therapeutic Assessment Multiple sclerosis – DelveInsight's Analytical Perspective Late Stage Products (Phase III) IMU-838: Immunic Therapeutics Drug profiles in the detailed report….. Mid Stage Products (Phase II) BIIB091: Biogen Drug profiles in the detailed report….. Early Stage Products (Phase I) NeuroVax: Immune Response BioPharma Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Multiple sclerosis Key Companies Multiple sclerosis Key Products Multiple sclerosis- Unmet Needs Multiple sclerosis- Market Drivers and Barriers Multiple sclerosis- Future Perspectives and Conclusion Multiple sclerosis Analyst Views Multiple sclerosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
